Methotrexate-d3 - CAS 432545-63-6

Methotrexate-d3 - CAS 432545-63-6 Catalog number: BADC-01445

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Methotrexate-d3 is the deuterated version of Methotrexate. Methotrexate (Amethopterin) is an antimetabolite and antifolate that inhibits dihydrofolate reductase, which prevents the conversion of folate to tetrahydrofolate and inhibits DNA synthesis. Methotrexate is also an immunosuppressant and antineoplastic agent used in rheumatoid arthritis and researched in various cancers (such as acute lymphoblastic leukemia).

Category
ADCs Cytotoxin
Product Name
Methotrexate-d3
CAS
432545-63-6
Catalog Number
BADC-01445
Molecular Formula
C20H19D3N8O5
Molecular Weight
457.46
Purity
95% by HPLC; 95% atom D
Methotrexate-d3

Ordering Information

Catalog Number Size Price Quantity
BADC-01445 -- $-- Inquiry

Related Molecules

Description
Methotrexate-d3 is the deuterated version of Methotrexate. Methotrexate (Amethopterin) is an antimetabolite and antifolate that inhibits dihydrofolate reductase, which prevents the conversion of folate to tetrahydrofolate and inhibits DNA synthesis. Methotrexate is also an immunosuppressant and antineoplastic agent used in rheumatoid arthritis and researched in various cancers (such as acute lymphoblastic leukemia).
Synonyms
Methotrexate-d3; Methotrexate-d3, Technical Grade 85per cent; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-(trideuteriomethyl)amino]benzoyl]amino]pentanedioic acid; L-Glutamic acid,N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methyl-d3-amino]benzoyl]-(9ci)
IUPAC Name
(2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-(trideuteriomethyl)amino]benzoyl]amino]pentanedioic acid
Canonical SMILES
CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
InChI
InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1/i1D3
InChIKey
FBOZXECLQNJBKD-FUPFOCIHSA-N
Density
1.5±0.1 g/cm3
Solubility
Soluble in DMSO
Melting Point
>223°C (dec.)
Appearance
Yellow to Orange Solid
Quantity
Milligrams-Grams
Storage
Store at -20°C, under inert atmosphere
Pictograms
Acute Toxic; Health Hazard
Signal Word
Danger
1. Methotrexate in dermatology
Carolyn A Bangert, Melissa I Costner Dermatol Ther . 2007 Jul-Aug;20(4):216-28. doi: 10.1111/j.1529-8019.2007.00135.x.
Methotrexate is a folic acid analog pioneered for use in inflammatory diseases by dermatologists, and used successfully for over 40 years for a wide variety of cutaneous diseases. In addition to its antiproliferative properties, methotrexate has other more recently recognized anti-inflammatory properties related to its effects on adenosine. Further research concerning its mechanism of action and genetic enzymatic variations suggest future possibilities for maximizing therapy and predicting adverse events. In this review the present authors will explore methotrexate's pharmacokinetics, mode of administration, dosing guidelines, side effect profile, and medication interactions. In addition, the present authors hope to offer practical guidelines for dose initiation and adjustment, and to summarize new research on its mechanism of action and implications for future therapy.
2. The use of methotrexate in dermatology: a review
H Miles Prince, Tim O'Brien, Sarah Shen, Christopher J McCormack, Lei Mee Yap Australas J Dermatol . 2012 Feb;53(1):1-18. doi: 10.1111/j.1440-0960.2011.00839.x.
Methotrexate is a synthetic folic acid analogue valued for both its anti-proliferative and anti-inflammatory properties. Considered one of the original immune-modifying agents, it is used widely for the treatment of steroid-recalcitrant inflammatory diseases. While there are abundant studies documenting its efficacy in rheumatic diseases, the use of methotrexate for dermatological conditions, with the exception of psoriasis, has yet to be comprehensively explored. This two-part review firstly outlines current data concerning the pharmacology of methotrexate, including its mechanism of action, side-effect profile and recommended therapeutic approach, and, secondly, examines the emerging evidence for methotrexate's efficacy in a wide range of cutaneous disorders.
3. Methotrexate therapy
G N Schep Can J Gastroenterol . 1998 Jan-Feb;12(1):26-7.
Methotrexate may be very helpful for your illness if proper care is taken in the use of this medication. Follow your physician's instructions faithfully. Take methotrexate weekly as directed. Notify your physician at once if an accidental overdose is suspected or if you develop fever, cough or shortness of breath. If you develop vomiting, there is a change in your pattern of diarrhea or you suspect that you are dehydrated, notify your physician before taking the next dose of methotrexate. Do not start or change any medicine without first checking with your physician. Avoid or severely restrict alcohol, including wine and beer. Obtain the blood tests ordered by your physician. Avoid pregnancy during and for several months after taking methotrexate. Keep methotrexate out of the reach of children. It has been prescribed for your current medical problem and must not be given to other people.
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Historical Records: S-methyl DM1 | ε-Amanitin | Methotrexate-d3
Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Questions & Comments
Verification code
Send Inquiry
Verification code
Resources & Supports
Inquiry Basket